These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
646 related articles for article (PubMed ID: 26727921)
1. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer. de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921 [TBL] [Abstract][Full Text] [Related]
2. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
3. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Sluiter NR; de Cuba EM; Kwakman R; Meijerink WJ; Delis-van Diemen PM; Coupé VM; Beliën JA; Meijer GA; de Hingh IH; te Velde EA Clin Exp Metastasis; 2016 Apr; 33(4):297-307. PubMed ID: 26873137 [TBL] [Abstract][Full Text] [Related]
4. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center. Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715 [TBL] [Abstract][Full Text] [Related]
5. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience. Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491 [TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239 [TBL] [Abstract][Full Text] [Related]
7. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis. van Oudheusden TR; Braam HJ; Nienhuijs SW; Wiezer MJ; van Ramshorst B; Luyer MD; Lemmens VE; de Hingh IH Ann Surg Oncol; 2014 Aug; 21(8):2621-6. PubMed ID: 24671638 [TBL] [Abstract][Full Text] [Related]
8. Histologic and Immunohistochemical Alterations Associated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy. Wagner P; Boone B; Ramalingam L; Jones H; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh H; Choudry H; Bartlett D Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S588-95. PubMed ID: 25948159 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812 [TBL] [Abstract][Full Text] [Related]
10. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC. Sluiter NR; Rovers KP; Salhi Y; Vlek SL; Coupé VMH; Verheul HMW; Kazemier G; de Hingh IHJT; Tuynman JB Ann Surg Oncol; 2018 Aug; 25(8):2347-2356. PubMed ID: 29855834 [TBL] [Abstract][Full Text] [Related]
11. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149 [TBL] [Abstract][Full Text] [Related]
12. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455 [TBL] [Abstract][Full Text] [Related]
13. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983 [TBL] [Abstract][Full Text] [Related]
14. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy. Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771 [TBL] [Abstract][Full Text] [Related]
15. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744 [TBL] [Abstract][Full Text] [Related]
16. P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Yong ZZ; Tan GHC; Shannon N; Chia C; Teo MCC World J Surg Oncol; 2019 Aug; 17(1):138. PubMed ID: 31391066 [TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B J Surg Oncol; 2014 Jun; 109(8):841-7. PubMed ID: 24619813 [TBL] [Abstract][Full Text] [Related]
18. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116 [TBL] [Abstract][Full Text] [Related]
19. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin. Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745 [TBL] [Abstract][Full Text] [Related]
20. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]